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Abstract 
Background: Research into the effects of asthma treatments on the extra-pulmonary symptoms of severe asthma 
is limited by the absence of a suitable questionnaire. The aim was to create a questionnaire suitable for intervention 
studies by selecting symptoms that are statistically associated with asthma pathology and therefore may improve 
when pathology is reduced.
Methods: Patients attending a specialist asthma clinic completed the 65-item General Symptom Questionnaire 
(GSQ-65), a questionnaire validated for assessing symptoms of people with multiple medically unexplained symp-
toms. Lung function (FEV1%) and cumulative oral corticosteroids (OCS) calculated from maintenance dose plus 
exacerbations were obtained from clinic records. Pathology was represented by the two components of a principal 
component analysis (PCA) of FEV1% and OCS. LASSO regression was used to select symptoms that had high coeffi-
cients with these two principal components and occurred frequently in severe asthma.
Results: 100 patients provided data. PCA revealed two components, one where FEV1% and OCS were inversely 
related and another where they were directly related. LASSO regression revealed 39 symptoms with non-zero coeffi-
cients on one or more of the two principal components from which 16 symptoms were selected for the GSQ-A on the 
basis of magnitude of coefficient and frequency. Asthma symptoms measured by asthma control questionnaires were 
excluded. The GSQ-A correlated 0.33 and − 0.34 (p = 0.001) with the two principal components.
Conclusion: The GSQ-A assesses the frequency of 16 heterogenous non-respiratory symptoms that are associated 
with asthma severity using the statistical combination of FEV1% and OCS.
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Background
The experience of people with severe asthma differs in 
several ways compared to those with mild or moderate 
asthma including extra-pulmonary symptoms (i.e., symp-
toms beyond the lung). There are two possible aetiolo-
gies. First, there are those symptoms that have no causal 
relationship with the underlying lung pathology, includ-
ing the symptoms of unrelated co-morbidities and symp-
toms resulting from the side effects of treatment. Second, 
there are those that have some form of direct or indirect 
causal connection with asthma pathology, mediated, for 
example, through the interaction between specific and 
non-specific inflammatory mediators.
All extra-pulmonary symptoms are relevant to clinical 
practice and, because these symptoms are very varied, 
can be measured by any of the several general symptom 
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questionnaires that have been developed for other pur-
poses such as the 164-item COMPASS [1] or its shorter 
31-item version the COMPASS-31 [2] designed to assess 
neurological symptoms, the PILL designed for the gen-
eral population [3] or the General Symptom Question-
naire (GSQ-65) designed to assess the symptomatology of 
people with a range of medically unexplained symptoms 
that are associated with a combination of neurological, 
immune and endocrine abnormalities [4]. Although these 
questionnaires cover a wide range of different symptoms 
and can be useful in clinical practice, they are long and 
not optimised for studies of interventions for the treat-
ment of asthma which directly target asthma pathology
Pharmacological and non-pharmacological interven-
tions that reduce asthma pathology should reduce those 
extra-pulmonary symptoms that are causally influenced 
by asthma pathology. If a general-purpose symptoms 
questionnaire is used in a clinical trial, then the scale may 
include items that are not improved by pathology reduc-
tion. Additionally, it is unclear whether any reduction 
in extra-pulmonary symptoms is due to the cessation of 
treatments that cause side effects (e.g., oral corticoster-
oids) or due to the pathology reducing effect of the treat-
ment itself.
The aim of this study was to create a preliminary severe 
asthma specific extra-pulmonary questionnaire by select-
ing extra-pulmonary symptoms from a generic symptom 
questionnaire. The General Symptom Quesitonnaire-65 
(GSQ-65) was designed to assess the varied and overlap-
ping symptoms of people with medically unexplained 
symptoms, including people diagnosed with fibromyal-
gia, chronic fatigue syndrome (CFS) and irritable bowel 
syndrome (IBS). Common comorbidities of asthma 
include fibromyalgia [5–7], IBS [5, 8–10], and gastroe-
sophageal disease (GORD) [11, 12].
There are two ways of selecting symptoms from the 
GSQ-65 for use in asthma clinical trials. One is to use the 
full scale in a clinical trial and then select those symp-
toms that are most sensitive to change. The disadvantage 
of this method is that item selections would be based on 
response to a particular treatment. As different treat-
ments can affect extra-pulmonary symptoms in different 
ways, any resulting questionnaire will be biased towards 
the treatment that was used in its derivation. We used 
an alternative method, which is to select items that are 
related to asthma pathology, as this method produces a 
selection of symptoms that is unbiased towards any par-
ticular treatment. In this study we took lung function as 
the primary indicator of asthma pathology and cumula-
tive oral corticosteroid (OCS) use over 12 months as a 
secondary indicator calculated from exacerbations and 
maintenance dose. We selected symptoms that vary with 
lung function and cumulative OCS but also restricted the 
symptoms to those whose frequency and other proper-
ties make them suitable for use in a clinical trial.
Methods
Participants
Patients diagnosed with severe asthma as defined by 
guidelines [13] took part in the study. Inclusions cri-
terion was aged ≥  16 years and exclusion criterion was 
another condition that could contribute significantly to 
symptoms.
Questionnaire
General symptom questionnaire (GSQ). The 65-item 
questionnaire assesses the frequency of somatic and psy-
chological symptoms on a 6 point Likert scale (the value 
scoring for each response shown in brackets): “Never or 
almost never” (1), “Less than 3 or 4 times per year” (2), 
“Every month or so” (3), “Every week or so” (4), “More 
than once per week” (5) or “Every day” (6) [4].
Clinic data
We obtained two measures of asthma severity from clinic 
records, (a) percentage predicted forced expiratory vol-
ume in the first second (FEV1%) and (b) cumulative oral 
corticosteroids (OCS) exposure (mg/year). OCS dose was 
calculated by combining the daily dose and estimated 
dose for exacerbations following GINA guidelines [14] 
equating to 280 mg of OCS per exacerbation.
Procedure
Written informed consent was obtained after which par-
ticipants  completed the questionnaire either at home or 
during their clinic visit. The questionnaire data were col-
lected at the same time as other questionnaires data were 
collected for a study reported elsewhere [15].
Statistics
The reduction of the 65 item set of the GSQ-65 was con-
ducted in three stages. In Stage 1, one of any pair of items 
correlating at >  0.7 was removed so that the selected 
items contributed different variation to the overall score. 
The item of the pair with the lowest frequency of occur-
rence was removed. In Stage 2 items were removed if 
they had a minimal relationship with pathology. Pathol-
ogy was assessed by pulmonary function (FEV1%) and 
cumulative oral corticosteroid dose (OCS). High FEV1% 
and low OCS indicate low pathology, but the two vari-
ables are causally linked as treatment with OCS increases 
FEV1%. Therefore, in order to provide a combined meas-
ure of pathology, OCS and FEV1% were entered into a 
principal component analysis (PCA). The resulting two 
components (PC1 and PC2) represent the combination 
of OCS and FEV1% and therefore a better representation 
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of pathology than separate use of the two variables [16, 
17]. PC1 and PC2 were then used as the dependent vari-
ables and the remaining GSQ-65 items as independent 
variables in a penalized linear regression that was solved 
by applying the Least Absolute Shrinkage and Selec-
tion Operator (LASSO) on the whole sample. LASSO is 
a regression analysis method that performs both vari-
able selection and regularization in order to enhance 
the prediction accuracy and interpretability of the sta-
tistical model [18]. The trade-off between interpretabil-
ity and prediction accuracy is controlled by a shrinkage 
parameter that is estimated through a cross-validation 
procedure after the standardization of both dependent 
and independent variables [19]. In the present analysis, 
LASSO checks the association between symptoms (items 
of the GSQ-65) and pathology (PC1 and PC2), assigns a 
weight to each symptom and eliminates those symptoms 
that are poorly associated with pathology by assigning a 
zero coefficient. The symptoms that still have a non-zero 
coefficient are then selected to be part of the model.
LASSO regression has advantages over other methods 
of item selection particularly when there are large num-
bers of independent variables which may be even more 
numerous than the observations [20]. In such conditions, 
the presence of strongly correlated independent variables 
is overcome by excluding the least associated with the 
dependent variable [21]. Thus, LASSO regression elimi-
nates irrelevant symptoms early on and therefore makes 
interpretation easier. Built on linear modeling, LASSO 
tries to find the relationship between dependent and 
independent variables where the coefficients correspond 
to the amount of expected change in the dependent 
variable for a unit increase/decrease in the independent 
variable (this is why in the output there are positive and 
negative coefficients). The standardization of independ-
ent variables guarantees that the coefficients are not 
selected because of their scale but rather their relative 
importance [22].
At Stage 2, all items with zero coefficients from the 
LASSO regression on both principal components were 
removed. At Stage 3, items from those remaining were 
selected on the basis of their coefficients, frequency of 
occurrence and clinical properties.
Correlations with the GSQ-A are Pearson correlations. 
Internal consistency was assessed by Cronbach’s alpha.
Ethics
The study, as well as questionnaire data collection and 
access to patient records, was approved by the Univer-
sity Hospitals Plymouth NHS Trust and the Newcastle 
& North Tyneside Research Ethics Committee and the 
Newcastle & North Tyneside Health Research Authority 
(ethical approval number 16/NE/0188, IRAS ID: 207601).
Results
Completed questionnaires were received from 100 
patients, mean age (SD) = 54 (15) years 63% were female. 
Sample characteristics are shown in Table 1.
Three items were removed at Stage 1 because of high 
inter-correlations with other items leaving 62 items. Stage 
2 requires a measure of pathology to be constructed from 
the combination of FEV1% and cumulative OCS. When 
these two variables were entered into a principal com-
ponent analysis, the first component accounted for 64% 
of the variance. In PC1 FEV1% loaded 0.80 and cumula-
tive OCS loaded −  0.8. Thus, this component indicates 
healthy participants with comparatively good pulmonary 
function with comparatively low requirement for OCS: 
it is an inverse measure of the severity of pathology. The 
second component accounted for 36% of the variance. 
In PC2 FEV1% loaded 0.6 and OCS loaded 0.6. Because 
both loadings are positive, the second component repre-
sents the improvement to FEV1% achieved by OCS, i.e., 
where comparatively better FEV1% is accompanied by 
high OCS.
The two measures of pathology (PC1 and PC2) 
were then used as the two dependent variables in the 
LASSO regression where 62 items were the independ-
ent variables. Table 2 shows the 23 items that have zero 
Table 1 Baseline characteristics* if study population.
*Mean values (confidence intervals) of sample unless stated otherwise
Total sample = 100 63 females, 37 males
Age, mean (range) 54.19–81
FEV1% predicted 69.7 (66.1–73.4)
BMI 31.6 (29.9–33.3)
Number of severe exacerbations in the previous 12 months 2.1 (1.4–2.7)
Hospital admissions in the previous 12 months 0.3 (0–0.8)
Number (percent) on maintenance oral corticosteroids 38 (38%)
Number (percent) on biologic therapy 32 (32%)
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coefficients and therefore excluded from further analy-
sis at Stage 2.
The coefficients of the remaining 39 items are shown 
in Table  3. These items all have a plausible relation-
ship with asthma pathology. At Stage 3 a priority list 
of symptoms was formed by taking all those items with 
a frequency of 25% or more that either had a LASSO 
coefficient of 0.08 (in absolute value) or more on one 
component or had coefficients of any magnitude on 
both components. Symptoms with a LASSO coef-
ficient of 0.035 were then added to the priority list if 
their frequency was greater than 40% per week. From 
this priority list of 22 items, four items were removed 
because they were associated with night disturbance or 
were symptoms linked to atopy. From the remaining 18 
items two further items were removed, one (intolerant 
of some food) because perceived change on this item is 
likely to be slow and one (difficulty concentrating) was 
removed because there are two other cognitive items 
included in the priority list. The symptoms of ‘very 
vivid dreams’ and ‘nightmares, night terrors’ are corre-
lated 0.53. The former is more than twice as frequent 
than the latter and makes the criterion of selection into 
the GSQ-A even though the latter is more strongly 
associated with pathology. The selection process pro-
duces a 16 symptom questionnaire, the GSQ-A, the 
items of which are shown in Table 3 along with catego-
ries indicating why an item was included or excluded.
The correlation between the GSQ-A and GSQ-65 was 
0.97, p < 0.001. The GSQ-A correlated with cumulative 
OCS, 0.46, p < 0.001, but not with FEV1%. − 0.06, ns. 
The GSQ-A correlated − 0.33, p = 0.01 with PC1 and 
0.34, p =  0.001 with PC2. The GSQ-A correlated 0.22 
(p  <  0.05) with BMI. For our sample, the mean of the 
GSQ-A was 2.06, the standard deviation was 1.2 and 
each item was scored from 0 to 5.
Discussion
The aim of this study was to select symptoms from the 
GSQ-65 that were related to asthma pathology and 
whose distribution and type increased the likelihood 
of detecting response to an intervention  that reduced 
asthma pathology. FEV1% and cumulative OCS were 
used as two interacting measures of pathology and the 
combination determined by PCA. The PCA provided two 
components, a primary component where high FEV1% 
was associated with low OCS, indicative of a general ten-
dency for better health, but also a secondary component 
where high FEV1% was associated with high OCS. The 
second component expresses the positive effect that OCS 
can have on FEV1%.
In order to select items for the new questionnaire, we 
wanted to exclude items that had a poor relation with 
asthma pathology, and therefore unlikely to be improved 
by asthma treatment. Gastro-oesophageal reflux disease 
is a comorbidity of asthma caused by known mecha-
nisms: it exacerbates asthma due to  distal oesophageal 
stimulation with acid [23–25]. Asthma treatments are 
therefore unlikely to improve the symptom of heartburn, 
and though treatment of GORD has the potential for 
improving asthma symptoms results are mixed [26–28]. 
In our study, the symptom of heartburn failed to be suffi-
ciently associated with asthma pathology as measured by 
the LASSO analysis and was rejected at the second stage 
of item reduction.
Fibromyalgia is a known comorbidity of severe asthma 
[6] and many symptoms of fibromyalgia were found, 
by our method, to be related to asthma pathology and 
were included in the GSQ-A. Like other medically unex-
plained syndromes, the pathophysiology of fibromyalgia 
is uncertain because, although there are many biologi-
cal abnormalities, none are specific, and so diagnosis is 
based on symptoms. Pain is a primary symptom of fibro-
myalgia but of the several pain items in the GSQ-65, 
only one is associated with asthma severity and included 
in the GSQ-A, namely, ‘pain moving from one place of 
body to another on different days’. This symptom is highly 
indicative of central sensitivity syndrome [29] in contrast 
to the peripheral pain measured by other symptoms in 
the GSQ-65 and that can have a variety of causes. ‘Sen-
sitive or tender skin’ is a second symptom indicative of 
central sensitivity syndrome and included in the GSQ-A. 
Two further symptoms indicative of central sensitivity 
syndrome (sensitivity to noise and sensitivity to bright 
lights) have lower coefficients with asthma pathology and 
so were included at Stage 2 but rejected at Stage 3.
Table 2 23 items excluded at Stage 2 of item selection.
Headaches Irritable
Stomach pain Jittery easily startled, often worried
Chest pain More clumsy than others
Back pain Difficulty getting to sleep
Pain increasing the day after 
you are active
Blocked nose
Fatigue for no reason Itchy eyes
Very cold hands or feet Restless legs
Diarrhoea Dizziness or loss of balance
Constipation Cramps in leg foot or bottom
Heartburn Problems urinating, frequency hesitancy 
or pain
Depression Feeling out of breath for no reason
Feeling anxious for no reason
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Two cognitive symptoms are included in the GSQ-A, 
namely ‘mental fog’ which is reported in 91% of peo-
ple with fibromyalgia and 93% of people with CFS, and 
‘memory problems’ which is reported in 90% of peo-
ple with fibromyalgia and 91% of people with CFS [5]. 
Although the pathophysiology of fibromyalgia lacks 
consensus, it is possible that the aetiology of asthma and 
fibromyalgia are associated due to common inflamma-
tory mechanisms as inflammation is a known pathophys-
iology of fibromyalgia [30, 31].
Although a comparatively short questionnaire, the 
symptoms of the GSQ-A are very heterogenous. In 
Table 3 Results of LASSO regression with PC1 and PC2 scores as dependent variables, percentage reporting symptom at least once 
weekly and criteria for symptom selection.
* a = Items on priority list; b = Items rejected due to association with asthma; c = items removed for other reasons. 1–16 symptoms to be included in the GSQ-A




% of people reporting at 




Swollen painful joints 0.000 0.011 39
Pain moving from one place of body to another on 
different days
− 0.087 0.038 34 a1
Sensitive or tender skin − 0.038 0.000 44 a2
Fatigue increasing the day after you are active 0.000 0.046 46 a3
Fatigue increasing after a cold or sore throat 0.000 0.020 34
Mental fog 0.100 0.000 46 a4
Difficulty concentrating 0.000 − 0.047 52 ac
Memory problems − 0.101 − 0.090 48 a5
Easily feel too cold − 0.024 0.000 47
Easily feel too hot sweating − 0.051 − 0.017 61 a6
Thirsty all the time 0.000 − 0.003 47
Bloating of the stomach − 0.083 0.000 44 a7
Nausea for no reason − 0.014 0.101 25 a8
Intolerant to some food 0.071 0.036 32 ac
Ringing in ears 0.061 0.063 34 a9
Very vivid dreams 0.000 − 0.051 40 a10
Nightmares night terrors 0.087 − 0.128 17
Sensitivity to bright lights 0.012 0.000 26
Sensitivity to noise 0.000 − 0.033 19
Waking up often at night 0.000 0.144 69 ab
Racing heart 0.000 0.065 43 a11
Hands tremble or shake − 0.091 − 0.027 56 a12
Face flushes 0.000 0.074 35 a13
Running nose 0.140 0.000 36 ab
Itchy skin 0.000 − 0.114 51 ab
Head cold sore throat or ‘flu − 0.116 0.000 6
Mouth ulcers sores in mouth 0.195 0.012 13
Skin rash − 0.034 0.046 17
Boils or pimples on face or body − 0.111 0.136 15
Twitching of eyelid 0.000 0.000 16
Twitching other than eyelid 0.000 0.109 14
Feeling faint 0.000 0.142 19
Numbness tingling pins and needles 0.000 − 0.107 44 a14
Loss of voice 0.076 − 0.081 13
Urinating two or more times per night − 0.148 0.000 47 ab
Blurred vision − 0.105 0.057 26 a15
Hair loss 0.000 0.196 18
Feeling very ill for no reason − 0.107 0.000 29 a16
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addition to two central sensitivity syndrome and two 
cognitive symptoms, the GSQ-A includes two gastric 
symptoms, one ocular symptom, one auditory symptom, 
two thermal regulation symptoms, four neurological 
symptoms and two symptoms (‘very vivid dreams’ and 
‘feeling unwell for no reason’) that could respond quickly 
to changes in health status. Neither anxiety, depression 
nor irritability feature in the GSQ-A. These symptoms 
have a variety causes and therefore the association with 
asthma pathology was too low to meet the requirement 
of the LASSO algorithm and so were rejected at Stage 2 
of the item reduction process. Despite their heterogene-
ity, the coefficient of internal consistency was very high 
at 0.93, confirming the use of the mean of the items as a 
single scale score.
A symptom can improve at follow up only if it is expe-
rienced at baseline. Consequently, a symptom question-
naire is sensitive to change in a given population only if 
the symptoms assessed are sufficiently common. Patients 
respond to the GSQ-A on a 6-point scale as they do on 
the GSQ-65. For ten of the 16 GSQ-A symptoms, 40% 
of patients reported a frequency of occurrence of either 
“Every week or so”, “More than once per week”, “Every 
day” i.e., one of the top three points of the 6-point scale. 
For a further three symptoms, 30% of patients reported a 
frequency of occurrence in one of the top three points of 
the 6-point scale. The questionnaire measures symptoms 
that vary in frequency but are sufficiently common to be 
sensitive to improvement in a population of people with 
severe asthma.
The PCA provided a way of combining FEV1% and 
cumulative OCS and it did so by producing two different 
indicators of pathology, PC1 and PC2. Examination of 
the component loadings shows that FEV1% and cumula-
tive OCS contribute approximately equally to the scores 
of PC1 and PC2. The GSQ-A mean (i.e. average of scores 
for each patient) correlated negatively with PC1, showing 
that healthy participants with better lung function and 
less requirement for OCS have fewer extra-pulmonary 
symptoms. However, the GSQ-A mean correlated posi-
tively with PC2, showing that participants whose com-
paratively better FEV1% was achieved by a comparatively 
high dose of OCS had more extra-pulmonary symptoms. 
FEV1% did not by itself correlate with either the GSQ-A 
mean or with the GSQ65 mean, and FEV1% is known to 
correlate poorly with other patient reported outcomes, so 
these findings support the use of PCA in creating indices 
of pathology from multiple causally related indicators of 
pathology [16, 17].
There are bidirectional causal connections between 
inflammation in the lung and non-specific inflammatory 
markers that creates an association between asthma and 
obesity [32]. The mean BMI of this group of patients was 
at the bottom of the range normally considered obese 
and BMI correlated significantly GSQ-A consistent with 
the hypothesis that the extra-pulmonary symptoms are 
linked to nonspecific inflammation [33, 34]. Nonspecific 
inflammation is linked to many other biological abnor-
malities through a network of biological causal influence 
[35]. The GSQ-A has been designed for interventions, 
including both pharmacological and non-pharmacologi-
cal interventions but use in this way requires validation 
in a further studies. There are many symptoms that create 
distress for the patient and measured by the GSQ-65 but 
not by the GSQ-A. If the aim is to detect the full range of 
extra-pulmonary symptoms a patient experiences as part 
of clinical assessment, then other questionnaires would 
be more appropriate, such as the GSQ-65 [4] which is 
designed for people with medically unexplained symp-
toms of varying kinds or the COMPASS [1, 2] which is 
designed for people with neurological symptoms. Never-
theless, the GSQ-65 and GSQ-A are highly correlated.
Limitations
This study describes the preliminary development of a 
questionnaire that requires validation in a larger popula-
tion. The items for the GSQ-A are a subset of the GSQ-65 
and there may be other extra-pulmonary symptoms that 
are not measured here. Prescription of biologics forms a 
binary variable and possible for this reason did not con-
tribute additional information about pathology. The data 
were collected from a single asthma clinic. Data from the 
GSQ-A is yet to be collected in a clinical trial, the sen-
sitivity of the scale to change is unknown and any such 
change does not necessarily reflect the impact on quality 
of life of these symptoms on patients.
Conclusions
The GSQ-A is a 16-item questionnaire designed to detect 
change in the extra-pulmonary symptoms of severe 
asthma resulting from asthma interventions. Symptoms 
were selected from the GSQ-65 on the basis of their rela-
tionship with asthma pathology and are not biased to 
favour a particular treatment. The questionnaire score is 
the mean, i.e., adding the scores of the individual items 
(each item is scored 0–5) and dividing by the total num-
ber of items, and following normal practice, one miss-
ing item is acceptable, two or more missing (i.e., > 10%) 
invalidates that patient’s data. The questionnaire is avail-
able as a Additional file 1 (GSQ-A).
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